CompletedPhase 2NCT02398435
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
Studying Adult-onset Still disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AB2 Bio Ltd.
- Principal Investigator
- Cem Gabay, Prof.Hospital University of Geneva
- Intervention
- Tadekinig alfa (recombinant human IL-18 binding protein)(biological)
- Enrollment
- 23 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2015 – 2016
Study locations (20)
- Hôpital Pellegrin, Bordeaux, France
- CHRU de Lille - Hôpital Claude Huriez, Lille, France
- Hôpital de la Croix Rousse, Lyon, France
- CHRU de Montpellier, Montpellier, France
- CHU de Nantes - Hôtel Dieu, Nantes, France
- CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière, Paris, France
- Strasbourg University Hospital, Strasbourg, France
- Innere Medizin II - Rheumatologie Schlosspark-Klinik, Berlin, Germany
- Medizinische Klinik - Rheumatologie und Klinische, Berlin, Germany
- Universitätsklinikum Erlangen, Erlangen, Germany
- Asklepios Klinik Altona, Hamburg, Germany
- St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr Rheumazentrum Ruhrgebiet, Herne, Germany
- Universitätsklinikum Jena Klinik für Innere Medizin III Rheumatologie/Osteologie, Jena, Germany
- Klinik Kirchheim, Kirchheim unter Teck, Germany
- Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02398435 on ClinicalTrials.govOther trials for Adult-onset Still disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07203001A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE3NCT05814159A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)Swedish Orphan Biovitrum
- RECRUITINGNCT04402086Rheumatology Patient Registry and BiorepositoryYale University
- RECRUITINGNCT03510442Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related ConditionsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- RECRUITINGNCT05927454Acostill ( RaDiCo Cohort) (RaDiCo Acostill)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02143986Glycosylated Ferritin in Macrophagic Activation SyndromesBrugmann University Hospital